Harnessing the Clinical Value of Biomarkers in MS:
Diagnosis, Assessment, and Therapeutic Sequencing

Share:
Credit Area      

Release Date: Aug 1, 2012          Expiration Date: Aug 1, 2013



Program Description


Multiple sclerosis is a complex disease with several mechanisms contributing to its pathophysiology. Early diagnosis and treatment is extremely important in MS because early intervention can help slow the disease process and the progression of disability. Biomarkers may be able to identify which processes are at work and hold promising value in the diagnosis and stratification of MS type, identification of disease stage, prediction of disease course, selection of treatment, detection of response to treatment, improvement of prognostic capabilities, and the evaluation of novel therapeutics. With recent advances in biomarker research, MS clinicians must have the knowledge and skills to appropriately incorporate the use of biomarkers into MS diagnosis and treatment.

The goal of this educational program is to improve clinicians’ understanding of emerging molecular biomarkers in MS and provide a better understanding of how these markers are related to pathologic processes, disease activity, and clinical progression, in order to improve patient care and outcomes.


Faculty


FRANCISCO J. QUINTANA, PhD (Chair)
Assistant Professor of Neurology, Center for Neurologic Diseases
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA
Read Biography

SUHAYL DHIB-JALBUT, MD
Professor with Tenure and Chairman
Department of Neurology
UMDNJ-Robert Wood Johnson Medical School
Chief, Neurology Service
Robert Wood Johnson University Hospital
New Brunswick, NJ
Read Biography

AARON E. MILLER, MD
Professor of Neurology
Medical Director, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Mount Sinai Medical Center
New York, NY
Read Biography


Target Audience


This activity is intended for neurologists and other health care providers actively involved in the care of patients with multiple sclerosis.

Educational Objectives


This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.

At the conclusion of this activity, participants should be able to demonstrate the ability to:

  • Recognize the limitations of the current standard-of-care in MS and the need to incorporate biomarkers into management decisions
  • Using biomarkers, develop algorithms to guide initiation and sequencing of disease-modifying therapy (DMT) for maximum potential impact
  • Apply diagnostic biomarkers to allow for earlier diagnosis of MS
  • Assess the clinical utility of biomarkers to monitor disease activity and response to DMT

Accreditation


This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Designation Statement


The Potomac Center for Medical Education designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     For questions regarding CME credit, the post-test, or evaluation, please email contact@potomacme.org


Disclosure Statement


The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

The steering committee and faculty reported the following with commercial interests.

Francisco J. Quintana, PhD: Consultant: Teva; Speaker: EMD Serono; Research: EMD Serono

Suhayl Dhib-Jalbut, MD: Consultant: Bayer, Biogen, EMD Serono, Teva; Investigator/Research Grants: Bayer, EMD Serono, Teva

Aaron Miller, MD: Consultant: Acorda, Nuron Biotech, Ono Pharmaceutical, Sanofi-Aventis, Teva; Consultant/Research Support: Biogen Idec, Novartis

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Matthew Horn, MD; Bradley Pine; Blair St. Amand; Jay Katz, Dana Simpler, MD: Nothing to Disclose


FDA Disclosure


The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.


System Requirements


In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.

Instructions for Participants and Obtaining CME Credit


There is no fee for this activity. To receive credit, participants must take the pre-test, view this CME activity in its entirety, and then complete the post-test and evaluation. To complete the evaluation online, choose the best answer to each question. The estimated time for completion of this activity is 1.25 hours. To receive their certificates, participants must demonstrate mastery of the presented material via the post-test.


Jointly Sponsored By


      

Supported By


Supported by an educational grant from:



By clicking the View/Register Button you are agreeing that you have read and understood the information on this page.